Randomized trial evaluates long-term outcomes in systemic sclerosis subgroups, highlighting ACA's role in disease progression.
Key Points
This research aims to evaluate long-term outcomes in systemic sclerosis, focusing on differences between patients with and without anti-centromere antibodies.
Analyzed demographic, clinical, and serological data from 2894 systemic sclerosis patients.
Assessed time to reach the MINIMISE endpoint, defined by various disease progression criteria.
Performed time to event analysis including Kaplan Meier estimates and Cox proportional hazards regression.
31.6% of patients reached the MINIMISE outcome in the first 10 years, with 543 from the limited cutaneous systemic sclerosis group.
Hazard ratio for event frequency in diffuse cutaneous systemic sclerosis vs. limited cutaneous systemic sclerosis was 4.93 (95% CI: 4.09-5.93, p < 0.001).
ACA-negative patients in limited cutaneous systemic sclerosis had more frequent events than ACA-positive patients, HR 0.49 (95% CI: 0.36-0.67, p < 0.001).